Search research articles
Contact Us
Filters
Showing results (111-120 of 168) with videos related to
Page
of 17
Sort By:
Oncogene
|
May 30, 2012
A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers
B Morancho, J L Parra-Palau, Y H Ibrahim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 3, 2005
Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer
C Camps, E Felip, J M Sanchez, et al.
Cancer Research
|
August 28, 2001
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments
J Albanell, J Codony-Servat, F Rojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials
E Felip, B Massuti, C Camps, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2012
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
B Markman, J Tabernero, I Krop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2000
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
J Baselga, D Pfister, M R Cooper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 27, 2019
Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial
E M Holmes, I Bradbury, L S Williams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2003
Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients
J Baselga, A Llombart-Cussac, M Bellet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2009
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
J Tabernero, F Ciardiello, F Rivera, et al.
Seminars in Oncology
|
February 1, 1996
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience
C Hudis, A Seidman, G Raptis, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 168) with videos related to
Sort By:
Page
of 17
Oncogene
|
May 30, 2012
A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers
B Morancho, J L Parra-Palau, Y H Ibrahim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 3, 2005
Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer
C Camps, E Felip, J M Sanchez, et al.
Cancer Research
|
August 28, 2001
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments
J Albanell, J Codony-Servat, F Rojo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 1998
Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials
E Felip, B Massuti, C Camps, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2012
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
B Markman, J Tabernero, I Krop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2000
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
J Baselga, D Pfister, M R Cooper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 27, 2019
Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial
E M Holmes, I Bradbury, L S Williams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2003
Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients
J Baselga, A Llombart-Cussac, M Bellet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 27, 2009
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
J Tabernero, F Ciardiello, F Rivera, et al.
Seminars in Oncology
|
February 1, 1996
Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience
C Hudis, A Seidman, G Raptis, et al.
Page
of 17